65P Preliminary results of a phase II multicenter, open-label study of fruquintinib monotherapy as third-line treatment in advanced pancreatic cancer

Autor: Guo, W., Qiong, W., Wang, Y., Li, Y., Yang, L.
Zdroj: In ESMO Open February 2024 9 Supplement 1
Databáze: ScienceDirect
Externí odkaz: